Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

Alberto Aimo; Giuseppe Vergaro; Andrea Ripoli; Antoni Bayes-Genis; Domingo A. Pascual Figal; Rudolf A. de Boer; Johan Lassus; Alexandre Mebazaa; Etienne Gayat; Tobias Breidthardt; Zaid Sabti; Christian Mueller; Hans-Peter Brunner-La Rocca; W. H. Wilson Tang; Justin L. Grodin; Yuhui Zhang; Paulo Bettencourt; Alan S. Maisel; Claudio Passino; James L. Januzzi; Michele Emdin

doi:10.1016/j.jchf.2016.12.016

Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

Alberto Aimo^*, Giuseppe Vergaro, Andrea Ripoli, Antoni Bayes-Genis, Domingo A. Pascual Figal, Rudolf A. de Boer, Johan Lassus, Alexandre Mebazaa, Etienne Gayat, Tobias Breidthardt, Zaid Sabti, Christian Mueller, Hans-Peter Brunner-La Rocca, W. H. Wilson Tang, Justin L. Grodin, Yuhui Zhang, Paulo Bettencourt, Alan S. Maisel, Claudio Passino, James L. JanuzziMichele Emdin

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

OBJECTIVES The aim of this study was to perform a meta-analysis of currently available data regarding the prognostic significance of soluble suppression of tumorigenecity-2 (sST2) concentration in acute heart failure (AHF).

BACKGROUND Concentration of sST2 may have prognostic value in AHF. A comprehensive assessment of all available studies regarding sST2 in AHF is lacking.

METHODS Three databases (MEDLINE, Cochrane Library, and Scopus) were searched. Inclusion criteria were follow-up studies, papers published in English, enrollment of patients with AHF, and availability of median hazard ratios for all-cause death and other outcome measures, when available.

RESULTS Ten studies were included, with a global population of 4,835 patients and a median follow-up duration of 13.5 months. The following global hazard ratios calculated for log(2)(sST2) were admission sST2 and all-cause death, 2.46 (95% confidence interval [CI]: 1.80 to 3.37; p <0.001); discharge sST2 and all-cause death, 2.06 (95% CI: 1.37 to 3.11; p <0.001); admission sST2 and cardiovascular death, 2.29 (95% CI: 1.41 to 3.73; p <0.001); discharge sST2 and cardiovascular death, 2.20 (95% CI: 1.48 to 3.25; p <0.001); admission sST2 and heart failure (HF) hospitalization, 1.21 (95% CI: 0.96 to 1.52; p = 0.060); discharge sST2 and HF hospitalization, 1.54 (95% CI: 1.03 to 2.32; p = 0.007); admission sST2 and all-cause death or HF hospitalization, 1.74 (95% CI: 1.24 to 2.45; p <0.001); and discharge sST2 and all-cause death or HF hospitalization, 1.63 (95% CI: 1.14 to 2.33; p <0.001).

CONCLUSIONS Plasma sST2 has prognostic value with respect to all-cause and cardiovascular death as well as the composite outcome of all-cause death or HF hospitalization, with both admission and discharge values having prognostic efficacy. Discharge sST2, but not admission sST2, is predictive of HF rehospitalization during follow-up. (C) 2017 by the American College of Cardiology Foundation.

Original language	English
Pages (from-to)	287-296
Number of pages	10
Journal	JACC: Heart Failure
Volume	5
Issue number	4
DOIs	https://doi.org/10.1016/j.jchf.2016.12.016
Publication status	Published - Apr 2017

Keywords

acute heart failure
meta-analysis
prognosis
sST2
INTENSIVE-CARE-UNIT
FAMILY-MEMBER ST2
ACUTE DYSPNEA
EJECTION FRACTION
MORTALITY
ASSOCIATION
BIOMARKERS
GUIDELINES
UTILITY
COHORT

Access to Document

10.1016/j.jchf.2016.12.016Licence: Free access - publisher

Cite this

Aimo, A., Vergaro, G., Ripoli, A., Bayes-Genis, A., Figal, D. A. P., de Boer, R. A., Lassus, J., Mebazaa, A., Gayat, E., Breidthardt, T., Sabti, Z., Mueller, C., Brunner-La Rocca, H.-P., Tang, W. H. W., Grodin, J. L., Zhang, Y., Bettencourt, P., Maisel, A. S., Passino, C., ... Emdin, M. (2017). Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 5(4), 287-296. https://doi.org/10.1016/j.jchf.2016.12.016

@article{5280e4584167405a8855d5800638bf7e,

title = "Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure",

abstract = "OBJECTIVES The aim of this study was to perform a meta-analysis of currently available data regarding the prognostic significance of soluble suppression of tumorigenecity-2 (sST2) concentration in acute heart failure (AHF).BACKGROUND Concentration of sST2 may have prognostic value in AHF. A comprehensive assessment of all available studies regarding sST2 in AHF is lacking.METHODS Three databases (MEDLINE, Cochrane Library, and Scopus) were searched. Inclusion criteria were follow-up studies, papers published in English, enrollment of patients with AHF, and availability of median hazard ratios for all-cause death and other outcome measures, when available.RESULTS Ten studies were included, with a global population of 4,835 patients and a median follow-up duration of 13.5 months. The following global hazard ratios calculated for log(2)(sST2) were admission sST2 and all-cause death, 2.46 (95% confidence interval [CI]: 1.80 to 3.37; p <0.001); discharge sST2 and all-cause death, 2.06 (95% CI: 1.37 to 3.11; p <0.001); admission sST2 and cardiovascular death, 2.29 (95% CI: 1.41 to 3.73; p <0.001); discharge sST2 and cardiovascular death, 2.20 (95% CI: 1.48 to 3.25; p <0.001); admission sST2 and heart failure (HF) hospitalization, 1.21 (95% CI: 0.96 to 1.52; p = 0.060); discharge sST2 and HF hospitalization, 1.54 (95% CI: 1.03 to 2.32; p = 0.007); admission sST2 and all-cause death or HF hospitalization, 1.74 (95% CI: 1.24 to 2.45; p <0.001); and discharge sST2 and all-cause death or HF hospitalization, 1.63 (95% CI: 1.14 to 2.33; p <0.001).CONCLUSIONS Plasma sST2 has prognostic value with respect to all-cause and cardiovascular death as well as the composite outcome of all-cause death or HF hospitalization, with both admission and discharge values having prognostic efficacy. Discharge sST2, but not admission sST2, is predictive of HF rehospitalization during follow-up. (C) 2017 by the American College of Cardiology Foundation.",

keywords = "acute heart failure, meta-analysis, prognosis, sST2, INTENSIVE-CARE-UNIT, FAMILY-MEMBER ST2, ACUTE DYSPNEA, EJECTION FRACTION, MORTALITY, ASSOCIATION, BIOMARKERS, GUIDELINES, UTILITY, COHORT",

author = "Alberto Aimo and Giuseppe Vergaro and Andrea Ripoli and Antoni Bayes-Genis and Figal, {Domingo A. Pascual} and {de Boer}, {Rudolf A.} and Johan Lassus and Alexandre Mebazaa and Etienne Gayat and Tobias Breidthardt and Zaid Sabti and Christian Mueller and {Brunner-La Rocca}, Hans-Peter and Tang, {W. H. Wilson} and Grodin, {Justin L.} and Yuhui Zhang and Paulo Bettencourt and Maisel, {Alan S.} and Claudio Passino and Januzzi, {James L.} and Michele Emdin",

year = "2017",

month = apr,

doi = "10.1016/j.jchf.2016.12.016",

language = "English",

volume = "5",

pages = "287--296",

journal = "JACC: Heart Failure",

issn = "2213-1779",

publisher = "ELSEVIER SCI LTD",

number = "4",

}

Aimo, A, Vergaro, G, Ripoli, A, Bayes-Genis, A, Figal, DAP, de Boer, RA, Lassus, J, Mebazaa, A, Gayat, E, Breidthardt, T, Sabti, Z, Mueller, C, Brunner-La Rocca, H-P, Tang, WHW, Grodin, JL, Zhang, Y, Bettencourt, P, Maisel, AS, Passino, C, Januzzi, JL & Emdin, M 2017, 'Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure', JACC: Heart Failure, vol. 5, no. 4, pp. 287-296. https://doi.org/10.1016/j.jchf.2016.12.016

TY - JOUR

T1 - Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

AU - Aimo, Alberto

AU - Vergaro, Giuseppe

AU - Ripoli, Andrea

AU - Bayes-Genis, Antoni

AU - Figal, Domingo A. Pascual

AU - de Boer, Rudolf A.

AU - Lassus, Johan

AU - Mebazaa, Alexandre

AU - Gayat, Etienne

AU - Breidthardt, Tobias

AU - Sabti, Zaid

AU - Mueller, Christian

AU - Brunner-La Rocca, Hans-Peter

AU - Tang, W. H. Wilson

AU - Grodin, Justin L.

AU - Zhang, Yuhui

AU - Bettencourt, Paulo

AU - Maisel, Alan S.

AU - Passino, Claudio

AU - Januzzi, James L.

AU - Emdin, Michele

PY - 2017/4

Y1 - 2017/4

N2 - OBJECTIVES The aim of this study was to perform a meta-analysis of currently available data regarding the prognostic significance of soluble suppression of tumorigenecity-2 (sST2) concentration in acute heart failure (AHF).BACKGROUND Concentration of sST2 may have prognostic value in AHF. A comprehensive assessment of all available studies regarding sST2 in AHF is lacking.METHODS Three databases (MEDLINE, Cochrane Library, and Scopus) were searched. Inclusion criteria were follow-up studies, papers published in English, enrollment of patients with AHF, and availability of median hazard ratios for all-cause death and other outcome measures, when available.RESULTS Ten studies were included, with a global population of 4,835 patients and a median follow-up duration of 13.5 months. The following global hazard ratios calculated for log(2)(sST2) were admission sST2 and all-cause death, 2.46 (95% confidence interval [CI]: 1.80 to 3.37; p <0.001); discharge sST2 and all-cause death, 2.06 (95% CI: 1.37 to 3.11; p <0.001); admission sST2 and cardiovascular death, 2.29 (95% CI: 1.41 to 3.73; p <0.001); discharge sST2 and cardiovascular death, 2.20 (95% CI: 1.48 to 3.25; p <0.001); admission sST2 and heart failure (HF) hospitalization, 1.21 (95% CI: 0.96 to 1.52; p = 0.060); discharge sST2 and HF hospitalization, 1.54 (95% CI: 1.03 to 2.32; p = 0.007); admission sST2 and all-cause death or HF hospitalization, 1.74 (95% CI: 1.24 to 2.45; p <0.001); and discharge sST2 and all-cause death or HF hospitalization, 1.63 (95% CI: 1.14 to 2.33; p <0.001).CONCLUSIONS Plasma sST2 has prognostic value with respect to all-cause and cardiovascular death as well as the composite outcome of all-cause death or HF hospitalization, with both admission and discharge values having prognostic efficacy. Discharge sST2, but not admission sST2, is predictive of HF rehospitalization during follow-up. (C) 2017 by the American College of Cardiology Foundation.

AB - OBJECTIVES The aim of this study was to perform a meta-analysis of currently available data regarding the prognostic significance of soluble suppression of tumorigenecity-2 (sST2) concentration in acute heart failure (AHF).BACKGROUND Concentration of sST2 may have prognostic value in AHF. A comprehensive assessment of all available studies regarding sST2 in AHF is lacking.METHODS Three databases (MEDLINE, Cochrane Library, and Scopus) were searched. Inclusion criteria were follow-up studies, papers published in English, enrollment of patients with AHF, and availability of median hazard ratios for all-cause death and other outcome measures, when available.RESULTS Ten studies were included, with a global population of 4,835 patients and a median follow-up duration of 13.5 months. The following global hazard ratios calculated for log(2)(sST2) were admission sST2 and all-cause death, 2.46 (95% confidence interval [CI]: 1.80 to 3.37; p <0.001); discharge sST2 and all-cause death, 2.06 (95% CI: 1.37 to 3.11; p <0.001); admission sST2 and cardiovascular death, 2.29 (95% CI: 1.41 to 3.73; p <0.001); discharge sST2 and cardiovascular death, 2.20 (95% CI: 1.48 to 3.25; p <0.001); admission sST2 and heart failure (HF) hospitalization, 1.21 (95% CI: 0.96 to 1.52; p = 0.060); discharge sST2 and HF hospitalization, 1.54 (95% CI: 1.03 to 2.32; p = 0.007); admission sST2 and all-cause death or HF hospitalization, 1.74 (95% CI: 1.24 to 2.45; p <0.001); and discharge sST2 and all-cause death or HF hospitalization, 1.63 (95% CI: 1.14 to 2.33; p <0.001).CONCLUSIONS Plasma sST2 has prognostic value with respect to all-cause and cardiovascular death as well as the composite outcome of all-cause death or HF hospitalization, with both admission and discharge values having prognostic efficacy. Discharge sST2, but not admission sST2, is predictive of HF rehospitalization during follow-up. (C) 2017 by the American College of Cardiology Foundation.

KW - acute heart failure

KW - meta-analysis

KW - prognosis

KW - sST2

KW - INTENSIVE-CARE-UNIT

KW - FAMILY-MEMBER ST2

KW - ACUTE DYSPNEA

KW - EJECTION FRACTION

KW - MORTALITY

KW - ASSOCIATION

KW - BIOMARKERS

KW - GUIDELINES

KW - UTILITY

KW - COHORT

U2 - 10.1016/j.jchf.2016.12.016

DO - 10.1016/j.jchf.2016.12.016

M3 - Article

C2 - 28189578

SN - 2213-1779

VL - 5

SP - 287

EP - 296

JO - JACC: Heart Failure

JF - JACC: Heart Failure

IS - 4

ER -